Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 6/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CCRL2 | O00421 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076953 | 1.00 | NLRP3 (0.55) | NLRP3GPR139GRIN1GRIN2BAKR1B1 | |
| SCHEMBL24076421 | 0.91 | NLRP3 (0.60) | NLRP3GPR139AKR1B1CHRNA7MAPT | |
| SCHEMBL24076330 | 0.91 | NLRP3 (0.60) | NLRP3GPR139AKR1B1CHRNA7MAPT | |
| SCHEMBL24076373 | 0.91 | NLRP3 (0.60) | NLRP3GPR139AKR1B1CHRNA7MAPT | |
| SCHEMBL24076375 | 0.87 | NLRP3 (0.59) | NLRP3GPR139GRIN1GRIN2BAKR1B1 | |
| SCHEMBL24076342 | 0.87 | NLRP3 (0.59) | NLRP3GPR139GRIN1GRIN2BAKR1B1 | |
| SCHEMBL24076981 | 0.86 | NLRP3 (0.55) | NLRP3GPR139AKR1B1MAPTCCR2 | |
| SCHEMBL24077186 | 0.86 | NLRP3 (0.55) | NLRP3GPR139AKR1B1MAPTCCR2 | |
| SCHEMBL24076963 | 0.86 | NLRP3 (0.55) | NLRP3GPR139AKR1B1MAPTCCR2 | |
| SCHEMBL24076340 | 0.85 | NLRP3 (0.59) | NLRP3GPR139AKR1B1CHRNA7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885GPR139 1471/4885GRIN1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.